Sidewinder Therapeutics, a biopharmaceutical company developing next-generation bispecific antibody-drug conjugates, announced the closing of an oversubscribed $137 million Series B financing round to advance its oncology pipeline into clinical development.
The financing was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from existing investor OrbiMed and new investors including Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and Alexandria Venture Investments.
Alongside the funding, several investors joined the company’s Board of Directors, including Daniel Estes of Frazier Life Sciences, Michal Silverberg of Novartis Venture Fund, Josh Richardson of Life Sciences at Goldman Sachs Alternatives, and John Hamer of DCVC Bio.
Founded in 2023, Sidewinder Therapeutics is focused on developing bispecific ADCs that target receptor co-complexes highly expressed in certain solid tumors. Its platform is designed to improve tumor specificity and drug delivery while minimizing impact on healthy cells.
The company’s pipeline includes programs targeting cancers with limited treatment options, including squamous cell carcinomas in lung and head and neck cancers, as well as gastrointestinal cancers such as colorectal cancer. Sidewinder expects to advance its lead program into clinical development in 2027.
The company has partnered with Lonza to leverage Synaffix’s site-specific linker-payload platform across multiple programs. With this latest round, Sidewinder has raised a total of $162 million to date.
KEY QUOTES:
“We are pleased to receive the support of this exceptional group of investors and their shared enthusiasm in advancing Sidewinder’s mission to develop next-generation bispecific ADCs for difficult to treat cancers. The ADC field is at an inflection point driven by technological breakthroughs enabling next-generation bispecific ADCs, and Sidewinder is eager to lead this wave of innovation and advance promising therapies for patients with cancer.”
Eric Murphy, Ph.D., Co-Founder And CEO Of Sidewinder Therapeutics
“Founded on compelling science and a differentiated approach, Sidewinder’s novel bispecific ADC pipeline has the potential to address key hurdles limiting safety and efficacy for this class of therapeutics. We believe that Sidewinder Therapeutics will significantly advance the ADC space and is well positioned to transform the treatment paradigm for cancer patients.”
Daniel Estes, Ph.D., General Partner At Frazier Life Sciences
